Blocking HCV entry as potential antiviral therapy

Future Virology

Volumn 7, Issue 6, 2012, Pages 547-561

  Vercauteren, Koen ^a   Leroux Roels, Geert ^a   Meuleman, Philip ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

antiviral therapy; humanized mice; liver transplantation; viral entry; viral hepatitis

Indexed keywords

ANTIVIRUS AGENT; ARBIDOL; BAFILOMYCIN; BJ 486K; BJ486K; CHLOROQUINE; CONCANAMYCIN A; DASATINIB; EPIGALLOCATECHIN GALLATE; ERLOTINIB; EZETIMIBE; GEFITINIB; HCV AB 65; HCV AB 68; HEPATITIS C ANTIBODY; JTK 652; LAPATINIB; NEUTRALIZING ANTIBODY; PI 88; POLYCLONAL ANTIBODY; RECOMBINANT PROTEIN; SCAVENGER RECEPTOR BI; SILIBININ; UNCLASSIFIED DRUG;

DRUG MEGADOSE; END STAGE LIVER DISEASE; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LIVER TRANSPLANTATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; VIRUS ATTACHMENT; VIRUS ENTRY;

HEPATITIS C VIRUS; MUS;

EID: 84861999779     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.12.47     Document Type: Review

References (153)

1. Zeuzem S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat. Clin. Pract. 5(11), 610-622 (2008).
2. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J. Hepatol. 56(Suppl. 1), S88-S100 (2012).
3. Peveling-Oberhag J, Zeuzem S, Hofmann WP. Antiviral tlherapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med. Microbiol. Immunol. 199(1), 1-10 (2010).
4. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents - a potentially lethal cocktail. Hepatology 54(1), 3-5 (2011).
5. Pohlmann S, Zhang J, Baribaud F et al. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J. Virol. 77(7), 4070-4080 (2003).
6. Pileri P, Uematsu Y, Campagnoli S et al. Binding of hepatitis C virus to CD81. Science 282(5390), 938-941 (1998). The discovery of CD81 as one of the HCV (co)receptors is described.
7. Scarselli E, Ansuini H, Cerino R et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21(19), 5017-5025 (2002). Describes the discovery of SR-BI as one of the HCV (co)receptors.
8. Evans MJ, Von Hahn T, Tscherne DM et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446(7137), 801-805 (2007). Discovery of the tight-junction protein claudin-1 as an essential coreceptor for HCV infection.
9. Ploss A, Evans MJ, Gaysinskaya VA et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457(7231), 882-886 (2009). Describes that occludin is an essential entry factor for HCV. In addition, the authors show that expression of human CD81 and human occludin renders mouse cells permissive to HCV infection. These data explain the species specificity of HCV and are a major step forward in the development of a mouse model for HCV infection.
10. Blanchard E, Belouzard S, Goueslain L et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J. Virol. 80(14), 6964-6972 (2006).
11. Meertens L, Bertaux C, Dragic T. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J. Virol. 80(23), 11571-11578 (2006).
12. Lavillette D, Pecheur EI, Donot P et al. Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J. Virol. 81(16), 8752-8765 (2007).
13. Burlone ME, Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J. Gen. Virol. 90(Pt 5), 1055-1070 (2009).
14. Timpe JM, Stamataki Z, Jennings A et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47(1), 17-24 (2008).
15. Witteveldt J, Evans MJ, Bitzegeio J et al. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J. Gen. Virol. 90(Pt 1), 48-58 (2009).
16. Brimacombe CL, Grove J, Meredith LW et al. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J. Virol. 85(1), 596-605 (2010).
17. Ciesek S, Westhaus S, Wicht M et al. Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles. J. Virol. 85(15), 7613-7621 (2011).
18. Meuleman P, Teresa Catanese M, Verhoye L et al. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 55(2), 364-372 (2012). Provides proof-of-concept that HCV infection can be prevented in vivo by blocking the SR-BI coreceptor. In contrast to anti-CD81 therapy, anti-SR-BI postexposure therapy can effectively prevent the spread of the virus within the infected liver. These data are encouraging for the develoment of a new therapeutic approach to prevent graft infection in HCV-infected liver transplant patients.
19. Lupberger J, Zeisel MB, Xiao F et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 17(5), 589-595 (2011).
20. Op De Beeck A, Voisset C, Bartosch B et al. Characterization of functional hepatitis C virus envelope glycoproteins. J. Virol. 78(6), 2994-3002 (2004).
21. Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, Dubuisson J. Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J. Virol. 84(19), 10159-10168 (2010).
22. Keck ZY, Machida K, Lai MM, Ball JK, Patel AH, Foung SK. Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies. Curr. Top. Microbiol. Immunol. 317, 1-38 (2008).
23. Chapel HM, Christie JM, Peach V, Chapman RW. Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. Clin. Immunol. 99(3), 320-324 (2001).
24. Pestka JM, Zeisel MB, Blaser E et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl Acad. Sci. USA 104(14), 6025-6030 (2007).
25. Farci P, Shimoda A, Wong D et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl Acad. Sci. USA 93(26), 15394-15399 (1996).
26. Mercer DF, Schiller DE, Elliott JF et al. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7(8), 927-933 (2001). Development of the first humanized small-animal model for the study of viral hepatitis.
27. Meuleman P, Libbrecht L, De Vos R et al. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 41(4), 847-856 (2005).
28. Vanwolleghem T, Bukh J, Meuleman P et al. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology 47(6), 1846-1855 (2008).
29. Meuleman P, Bukh J, Verhoye L et al. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology 53(3), 755-762 (2011).
30. Willems B, Ede M, Marotta P et al. Anti-HCV human immunoglobulins for the prevention of graft infection in HCV-related liver transplantation, a pilot study. J. Hepatol. 36(Suppl. 1), 32 (2002).
31. Davis GL, Nelson DR, Terrault N et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transplant. 11(8), 941-949 (2005).
32. Zhang P, Zhong L, Struble EB et al. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc. Natl Acad. Sci. USA 106(18), 7537-7541 (2009).
33. Eren R, Landstein D, Terkieltaub D et al. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J. Virol. 80(6), 2654-2664 (2006).
34. Galun E, Terrault NA, Eren R et al. Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. J. Hepatol. 46(1), 37-44 (2007).
35. Schiano TD, Charlton M, Younossi Z et al. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a Phase 2 randomized study. Liver Transplant. 12(9), 1381-1389 (2006).
36. Law M, Maruyama T, Lewis J et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14(1), 25-27 (2008).
37. Giang E, Dorner M, Prentoe JC et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc. Natl Acad. Sci. USA 109(16), 6205-6210 (2012).
38. Allander T, Drakenberg K, Beyene A et al. Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J. Gen. Virol. 81(Pt 10), 2451-2459 (2000).
39. Johansson DX, Voisset C, Tarr AW et al. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc. Natl Acad. Sci. USA 104(41), 16269-16274 (2007).
40. Hadlock KG, Lanford RE, Perkins S et al. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J. Virol. 74(22), 10407-10416 (2000).
41. Owsianka AM, Tarr AW, Keck ZY et al. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J. Gen. Virol. 89(Pt 3), 653-659 (2008).
42. Perotti M, Mancini N, Diotti RA et al. Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J. Virol. 82(2), 1047-1052 (2008).
43. Schofield DJ, Bartosch B, Shimizu YK et al. Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology 42(5), 1055-1062 (2005).
44. Broering TJ, Garrity KA, Boatright NK et al. Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J. Virol. 83(23), 12473-12482 (2009).
45. Flint M, Maidens C, Loomis-Price LD et al. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol. 73(8), 6235-6244 (1999).
46. Owsianka A, Tarr AW, Juttla VS et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J. Virol. 79(17), 11095-11104 (2005).
47. Gordon FD, Chung RT, Curry MP et al. Monoclonal antibody MBL-HCV1 suppresses return of HCV following liver transplantation. Hepatology 54(Suppl. 1), 1434A (2011).
48. Meunier JC, Russell RS, Goossens V et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J. Virol. 82(2), 966-973 (2008).
49. Verstrepen BE, Depla E, Rollier CS et al. Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies. J. Infect. Dis. 204(6), 837-844 (2011).
50. Choukhi A, Ung S, Wychowski C, Dubuisson J. Involvement of endoplasmic reticulum chaperones in the folding of hepatitis C virus glycoproteins. J. Virol. 72(5), 3851-3858 (1998).
51. Goffard A, Callens N, Bartosch B et al. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J. Virol. 79(13), 8400-8409 (2005).
52. Helle F, Wychowski C, Vu-Dac N, Gustafson KR, Voisset C, Dubuisson J. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J. Biol. Chem. 281(35), 25177-25183 (2006).
53. Meuleman P, Albecka A, Belouzard S et al. Griffithsin has antiviral activity against hepatitis C virus. Antimicrob. Agents Chemother. 55(11), 5159-5167 (2011).
54. Bertaux C, Daelemans D, Meertens L et al. Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology 366(1), 40-50 (2007).
55. Helle F, Goffard A, Morel V et al. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J. Virol. 81(15), 8101-8111 (2007).
56. Ciesek S, Von Hahn T, Colpitts CC et al. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology 54(6), 1947-1955 (2011).
57. Calland N, Albecka A, Belouzard S et al. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 55(3), 720-729 (2012).
58. Lavie M, Voisset C, Vu-Dac N et al. Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system. Hepatology 44(6), 1626-1634 (2006).
59. Cai Z, Cai L, Jiang J, Chang KS, Van Der Westhuyzen DR, Luo G. Human serum amyloid A protein inhibits hepatitis C virus entry into cells. J. Virol. 81(11), 6128-6133 (2007).
60. Von Hahn T, Lindenbach BD, Boullier A et al. Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology 43(5), 932-942 (2006).
61. Si Y, Liu S, Liu X et al. A human claudin-1 derived peptide inhibits hepatitis C virus entry. Hepatology doi:10.1002/hep.25685 (2012) (Epub ahead of print).
62. Pereira AA, Jacobson IM. New and experimental therapies for HCV. Nat. Rev. Gastroenterol. Hepatol. 6(7), 403-411 (2009).
63. Hezode C, Forestier N, Dusheiko G et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360(18), 1839-1850 (2009).
64. Gao M, Nettles RE, Belema M et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465(7294), 96-100 (2010).
65. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138(2), 447-462 (2009).
66. Lange CM, Sarrazin C, Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. Aliment. Pharmacol. Ther. 32(1), 14-28 (2010).
67. Liang Y, Shilagard T, Xiao SY et al. Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology 137(4), 1448-1458 (2009).
68. Pietschmann T. Virology: final entry key for hepatitis C. Nature 457(7231), 797-798 (2009).
69. Gardner JP, Durso RJ, Arrigale RR et al. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc. Natl Acad. Sci. USA 100(8), 4498-4503 (2003).
70. Cormier EG, Durso RJ, Tsamis F et al. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc. Natl Acad. Sci. USA 101(39), 14067-14072 (2004).
71. Barth H, Schafer C, Adah MI et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 278(42), 41003-41012 (2003).
72. Barth H, Schnober EK, Zhang F et al. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J. Virol. 80(21), 10579-10590 (2006).
73. Koutsoudakis G, Kaul A, Steinmann E et al. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J. Virol. 80(11), 5308-5320 (2006).
74. Lee E, Pavy M, Young N, Freeman C, Lobigs M. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antiviral Res. 69(1), 31-38 (2006).
75. Krepstakies M, Lucifora J, Nagel CH et al. A new class of synthetic peptide inhibitors block attachment and entry of human pathogenic viruses. J. Infect. Dis. doi:10.1093/infdis/jis273 (2012) (Epub ahead of print).
76. Popescu CI, Dubuisson J. Role of lipid metabolism in hepatitis C virus assembly and entry. Biol. Cell 102(1), 63-74 (2009).
77. Bartenschlager R, Penin F, Lohmann V, Andre P. Assembly of infectious hepatitis C virus particles. Trends Microbiol. 19(2), 95-103 (2011). Very detailed overview of the HCV assembly process.
78. Andre P, Komurian-Pradel F, Deforges S et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J. Virol. 76(14), 6919-6928 (2002).
79. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J. Virol. 80(5), 2418-2428 (2006).
80. Diaz O, Delers F, Maynard M et al. Preferential association of hepatitis C virus with apolipoprotein B48-containing lipoproteins. J. Gen. Virol. 87(Pt 10), 2983-2991 (2006).
81. Lindenbach BD, Meuleman P, Ploss A et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc. Natl Acad. Sci. USA 103(10), 3805 (2006).
82. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl Acad. Sci. USA 96(22), 12766-12771 (1999).
83. Molina S, Castet V, Fournier-Wirth C et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J. Hepatol. 46(3), 411-419 (2007).
84. Albecka A, Belouzard S, Op De Beeck A et al. Role of LDL receptor in the hepatitis c virus life cycle. Hepatology 55(4), 998-1007 (2011).
85. Andreo U, Maillard P, Kalinina O et al. Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection. Cell. Microbiol. 9(10), 2445-2456 (2007).
86. Maillard P, Walic M, Meuleman P et al. Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. PLoS One 6(10), e26637 (2011).
87. Boucheix C, Duc GH, Jasmin C, Rubinstein E. Tetraspanins and malignancy. Expert Rev. Mol. Med. 3, 1-17 (2001).
88. Bartosch B, Vitelli A, Granier C et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278(43), 41624-41630 (2003).
89. Zhang J, Randall G, Higginbottom A, Monk P, Rice CM, Mckeating JA. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J. Virol. 78(3), 1448-1455 (2004).
90. Cormier EG, Tsamis F, Kajumo F, Durso RJ, Gardner JP, Dragic T. CD81 is an entry coreceptor for hepatitis C virus. Proc. Natl Acad. Sci. USA 101(19), 7270-7274 (2004).
91. Molina S, Castet V, Pichard-Garcia L et al. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J. Virol. 82(1), 569-574 (2008).
92. Brazzoli M, Bianchi A, Filippini S et al. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J. Virol. 82(17), 8316-8329 (2008).
93. Coller KE, Berger KL, Heaton NS, Cooper JD, Yoon R, Randall G. RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog. 5(12), e1000702 (2009).
94. Harris HJ, Davis C, Mullins JG et al. Claudin association with CD81 defines hepatitis C virus entry. J. Biol. Chem. 285(27), 21092-21102 (2010).
95. Farquhar MJ, Hu K, Harris HJ et al. Hepatitis C virus induces CD81 and claudin-1 endocytosis. J. Virol. 86(8), 4305-4316 (2012).
96. Scheel TK, Gottwein JM, Jensen TB et al. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc. Natl Acad. Sci. USA 105(3), 997-1002 (2008).
97. Meuleman P, Hesselgesser J, Paulson M et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 48(6), 1761-1768 (2008).
98. Gottwein JM, Scheel TK, Jensen TB et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49(2), 364-377 (2009).
99. Vancompernolle SE, Wiznycia AV, Rush JR, Dhanasekaran M, Baures PW, Todd SC. Small molecule inhibition of hepatitis C virus E2 binding to CD81. Virology 314(1), 371-380 (2003).
100. Grove J, Nielsen S, Zhong J et al. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J. Virol. 82(24), 12020-12029 (2008).
101. Rhainds D, Brissette L. The role of scavenger receptor class B type I (SR-BI) in lipid trafficking. defining the rules for lipid traders. Int. J. Biochem. Cell. Biol. 36(1), 39-77 (2004).
102. Rigotti A, Miettinen HE, Krieger M. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocrine Rev. 24(3), 357-387 (2003).
103. Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-Dac N. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J. Biol. Chem. 280(9), 7793-7799 (2005).
104. Bartosch B, Verney G, Dreux M et al. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J. Virol. 79(13), 8217-8229 (2005).
105. Westhaus S, Ciesek S, Bankwitz D et al. 877 Oxidized low density lipoprotein (OxLDL) is a pan-genotype inhibitor of HCV entry that acts in a SR-BI dependent manner. J. Hepatol. 56, S341-S342 (2012).
106. Maillard P, Huby T, Andreo U, Moreau M, Chapman J, Budkowska A. The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins. FASEB J. 20(6), 735-737 (2006).
107. Dreux M, Dao Thi VL, Fresquet J et al. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog. 5(2), e1000310 (2009).
108. Catanese MT, Ansuini H, Graziani R et al. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J. Virol. 84(1), 34-43 (2010).
109. Bankwitz D, Steinmann E, Bitzegeio J et al. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J. Virol. 84(11), 5751-5763 (2010).
110. Zeisel MB, Koutsoudakis G, Schnober EK et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 46(6), 1722-1731 (2007).
111. Catanese MT, Graziani R, Von Hahn T et al. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J. Virol. 81(15), 8063-8071 (2007).
112. Lacek K, Vercauteren K, Grzyb K et al. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J. Hepatol. doi:10.1016/j.jhep.02.018 (2012) (Epub ahead of print).
113. Fafi-Kremer S, Fofana I, Soulier E et al. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J. Exp. Med. 207(9), 2019-2031 (2010).
114. Nieland TJ, Penman M, Dori L, Krieger M, Kirchhausen T. Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI. Proc. Natl Acad. Sci. USA 99(24), 15422-15427 (2002).
115. Dreux M, Pietschmann T, Granier C et al. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J. Biol. Chem. 281(27), 18285-18295 (2006).
116. Masson D, Koseki M, Ishibashi M et al. Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler. Thromb. Vasc. Biol. 29(12), 2054-2060 (2009).
117. Syder AJ, Lee H, Zeisel MB et al. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J. Hepatol. 54(1), 48-55 (2011).
118. Mittapalli GK, Jackson A, Zhao F et al. Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors. Bioorg. Med. Chem. Lett. 21(22), 6852-6855 (2011).
119. Lal-Nag M, Morin PJ. The claudins. Gen.Biol. 10(8), 235 (2009).
120. Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J. Cell Biol. 141(7), 1539-1550 (1998).
121. Zheng A, Yuan F, Li Y et al. Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. J. Virol. 81(22), 12465-12471 (2007).
122. Meertens L, Bertaux C, Cukierman L et al. The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J. Virol. 82(7), 3555-3560 (2008).
123. Yang W, Qiu C, Biswas N et al. Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus. J. Biol. Chem. 283(13), 8643-8653 (2008).
124. Krieger SE, Zeisel MB, Davis C et al. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 51(4), 1144-1157 (2010).
125. Fofana I, Krieger SE, Grunert F et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 139(3), 953-964.e1-e4 (2010).
126. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110(6), 669-672 (2002).
127. Tandon M, Vemula SV, Mittal SK. Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin. Ther. Targets 15(1), 31-51 (2011).
128. Chiba H, Osanai M, Murata M, Kojima T, Sawada N. Transmembrane proteins of tight junctions. Biochim. Biophys. Acta 1778(3), 588-600 (2008).
129. Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J. Virol. 83(4), 2011-2014 (2009).
130. Sainz B, Jr., Barretto N, Martin DN et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat. Med. 18(2), 281-285 (2012).
131. Yu L. The structure and function of Niemann-Pick C1-like 1 protein. Curr. Opin. Lipidol. 19(3), 263-269 (2008).
132. Altmann SW, Davis HR, Zhu LJ et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 303(5661), 1201-1204 (2004).
133. Temel RE, Tang W, Ma Y et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J. Clin. Invest. 117(7), 1968-1978 (2007).
134. Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. Expert Rev. Cardiovasc. Ther. 6(4), 447-470 (2008).
135. Wagoner J, Negash A, Kane OJ et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 51(6), 1912-1921 (2010).
136. Wagoner J, Morishima C, Graf TN et al. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS One 6(1), e16464 (2011).
137. Ferenci P, Scherzer TM, Kerschner H et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 135(5), 1561-1567 (2008).
138. Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J. Hepatol. 52(6), 951-952 (2010).
139. Beinhardt S, Rasoul-Rockenschaub S, Scherzer TM, Ferenci P. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. J. Hepatol. 54(3), 591-592; author reply 592-593 (2011).
140. Haid S, Novodomska A, Gentzsch J et al. A Plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes. Gastroenterology (2012) (In Press).
141. De Bruijne J, Bergmann JF, Weegink CJ et al. Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor. Antiviral Ther. 15(5), 765-773 (2010).
142. Baldick CJ, Wichroski MJ, Pendri A et al. A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog. 6(9), e1001086 (2010).
143. Boriskin YS, Pecheur EI, Polyak SJ. Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection. Virol. J. 3, 56 (2006).
144. Pecheur EI, Lavillette D, Alcaras F et al. Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol. Biochemistry 46(20), 6050-6059 (2007).
145. Boriskin YS, Leneva IA, Pecheur EI, Polyak SJ. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr. Med. Chem. 15(10), 997-1005 (2008).
146. Tscherne DM, Jones CT, Evans MJ, Lindenbach BD, McKeating JA, Rice CM. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J. Virol. 80(4), 1734-1741 (2006).
147. Matsumura T, Hu Z, Kato T et al. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology 137(2), 673-681 (2009).
148. Prentoe J, Jensen TB, Meuleman P et al. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J. Virol. 85(5), 2224-2234 (2011).
149. Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur. Heart J. 31(2), 149-164 (2010).
150. Wong-Staal F, Syder AJ, Mckelvy JF. Targeting HCV entry for development of therapeutics. Viruses 2(8), 1718-1733 (2010).
151. Zhu H, Wong-Staal F, Lee H et al. Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J. Infect. Dis. 205(4), 656-662 (2012).
152. Xiao F, Fofana I, Thumann C et al. Synergy of entry inhibitors and direct acting antivirals or interferon-alfa identifies novel antiviral combinations for hepatitis C virus infection. Presented at: 12ème Réunion du Reseau National Hépatites de l'ANRS. Paris, France, 26-27 January 2012.
153. Mensa L, Crespo G, Gastinger MJ et al. Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology 53(5), 1436-1445 (2011).